ASCO 2015 Highlights

The AVBCC Summit kicks off tomorrow with “Washington Perspectives on Cancer Care.” The first of 45 sessions begins promptly at 8:00 am with a diverse combination of industry experts discussing the current and prospective policy and legislative initiatives that will impact cancer care in the near future given the pending election. With the current state of the country, the goal of this session is to help separate the “noise” from reality.

Cranbury, NJ – The WEBside Chat is a dynamic take on the fireside chat. This award-winning format will be utilized at the 10th Association for Value-Based Cancer Care (AVBCC) Summit and Educational Program starting October 13 and running for 10 weeks. Each 90-minute session is focused on one of more than 30 topics currently affecting the cancer care ecosystem. Each session is packed with high-octane, unfiltered discussion; real-time topics; and balanced opinions by some of the top leaders in the cancer care continuum.

The Association for Value-Based Cancer Care (AVBCC) is proud to announce a jam-packed agenda for the 2020 Summit. This year’s summit features the who’s who in the cancer care ecosystem in an award winning WEBside chat setting. The summit consists of over 30, 90-minute sessions, approximately 5 days a week for 10 weeks, featuring top influencers, future trends, balanced opinions, real-time, real-world information, and unfiltered discussions from over 150 faculty.

When ASCO President Howard A. Burris III, MD, FACP, FASCO, chose the theme for the 2020 annual meeting—“Unite and Conquer: Accelerating Progress Together”—early last year, he never imagined that it would take on new meaning just 12 months later.

Oral relugolix given daily is superior to standard androgen-­deprivation therapy (ADT) with leuprolide (Lupron) in men with advanced prostate cancer, according to the results of the phase 3 HERO study, which were reported at the ASCO 2020 virtual annual meeting and published online before the meeting.

Treatment with osimertinib (Tagrisso) in the adjuvant setting significantly improves disease-­free survival (DFS) in patients with localized non–small-cell lung cancer (NSCLC) with an EGFR mutation, according to results presented by Roy S. Herbst, MD, PhD, FACP, FASCO, Chief of Medical Oncology, Yale Cancer Center, New Haven, CT, at the ASCO 2020 virtual annual meeting.

Nationally renowned oncologist Maurie Markman, MD, President of Medicine and Science at Cancer Treatment Centers of America, led a panel of experts in discussing how existing anticancer agents, such as kinase inhibitors and the corticosteroid dexamethasone, may be used for the treatment of patients with COVID-19 in a July webinar of the Association for Value-Based Cancer Care (AVBCC) on COVID-19.

As the complexity of cancer care continues to evolve, adhering to evidence-based treatment guidelines is a growing challenge for oncologists.

Cemiplimab-rwlc (Libtayo), a PD-1 inhibitor, has transformed the treatment of advanced ­cutaneous squamous-cell carcinoma (CSCC), significantly extending survival for patients.

New research highlights the importance of germline analysis in the identification of germline alterations for cancer treatment.